{"title":"Robot-assisted radical prostatectomy with the Hugo™ robot-assisted surgery system: A single-center initial experience in Japan","authors":"Kiyoshi Takahara, Tomonari Motonaga, Wataru Nakamura, Masanobu Saruta, Takuhisa Nukaya, Masashi Takenaka, Kenji Zennami, Manabu Ichino, Hitomi Sasaki, Ryoichi Shiroki","doi":"10.1111/ases.13342","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Recently, various novel robotic systems have been put into clinical use. The aim of the present study was to assess the perioperative outcomes of robot-assisted radical prostatectomy (RARP) using the Hugo™ RAS system, one of brand-new robot-assisted surgical platforms.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed RARP with the Hugo™ RAS system in 13 cases of localized prostate cancer (PCa) between August 2023 and February 2024 at our hospital. The perioperative outcomes of these 13 patients were assessed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median operative and console times were 197 (interquartile range [IQR], 187–228) and 134 min (IQR, 125–157), respectively. The median docking time was 7 min (IQR, 6–10), and the median estimated blood loss was 150 mL (IQR, 80–250). The vesical catheter was removed on postoperative day 6 in all cases. A positive surgical margin was observed in one patient (7.7%), and none experienced major perioperative complications, defined as Clavien–Dindo classification ≥3. The median postoperative length of stay was 8 days (IQR, 8–8.5).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This was the first study to focus on RARP using the Hugo™ RAS system in Japan. Although further investigations should be conducted to assess the long-term oncological and functional outcomes, the Hugo™ RAS system could provide safe and favorable perioperative outcomes for patients with localized PCa undergoing RARP.</p>\n </section>\n </div>","PeriodicalId":47019,"journal":{"name":"Asian Journal of Endoscopic Surgery","volume":"17 3","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ases.13342","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Endoscopic Surgery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ases.13342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Recently, various novel robotic systems have been put into clinical use. The aim of the present study was to assess the perioperative outcomes of robot-assisted radical prostatectomy (RARP) using the Hugo™ RAS system, one of brand-new robot-assisted surgical platforms.
Methods
We performed RARP with the Hugo™ RAS system in 13 cases of localized prostate cancer (PCa) between August 2023 and February 2024 at our hospital. The perioperative outcomes of these 13 patients were assessed.
Results
The median operative and console times were 197 (interquartile range [IQR], 187–228) and 134 min (IQR, 125–157), respectively. The median docking time was 7 min (IQR, 6–10), and the median estimated blood loss was 150 mL (IQR, 80–250). The vesical catheter was removed on postoperative day 6 in all cases. A positive surgical margin was observed in one patient (7.7%), and none experienced major perioperative complications, defined as Clavien–Dindo classification ≥3. The median postoperative length of stay was 8 days (IQR, 8–8.5).
Conclusions
This was the first study to focus on RARP using the Hugo™ RAS system in Japan. Although further investigations should be conducted to assess the long-term oncological and functional outcomes, the Hugo™ RAS system could provide safe and favorable perioperative outcomes for patients with localized PCa undergoing RARP.